Center-Authored Papers

Filters: First Letter Of Keyword is F  [Clear All Filters]
A B C D E [F] G H I J K L M N O P Q R S T U V W X Y Z   [Show ALL]
Fusion Proteins, gag-pol
Priddy FH, Brown D, Kublin J, Monahan K, Wright DP, Lalezari J, Santiago S, Marmor M, Lally M, Novak RM et al..  2008.  Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 46(11):1769-81. Abstract
Fusion Proteins, bcr-abl
Branford S, Fletcher L, Cross NCP, Müller MC, Hochhaus A, Kim D-W, Radich JP, Saglio G, Pane F, Kamel-Reid S et al..  2008.  Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials.. Blood. 112(8):3330-8. Abstract
Hochhaus A, Müller MC, Radich JP, Branford S, Kantarjian HM, Hanfstein B, Rousselot P, Kim D-W, Lipton JH, Bleickardt E et al..  2009.  Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value.. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 23(9):1628-33. Abstract
Hughes T, Saglio G, Branford S, Soverini S, Kim D-W, Müller MC, Martinelli G, Cortes J, Beppu L, Gottardi E et al..  2009.  Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(25):4204-10. Abstract
Kantarjian H, Cortes J, Kim D-W, Dorlhiac-Llacer P, Pasquini R, DiPersio J, Müller MC, Radich JP, Khoury JH, Khoroshko N et al..  2009.  Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up.. Blood. 113(25):6322-9. Abstract
Radich JP.  2012.  Measuring response to BCR-ABL inhibitors in chronic myeloid leukemia.. Cancer. 118(2):300-11. Abstract
Müller MC, Cortes JE, Kim D-W, Druker BJ, Erben P, Pasquini R, Branford S, Hughes TP, Radich JP, Ploughman L et al..  2009.  Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.. Blood. 114(24):4944-53. Abstract
Radich JP.  2009.  Molecular monitoring of patients with chronic myeloid leukemia: clinical examples from a non-trial setting.. Clinical lymphoma & myeloma. 9 Suppl 4:S391-4. Abstract
Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F et al..  2013.  European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.. Blood. 122(6):872-84. Abstract
Ito T, Kwon HY, Zimdahl B, Congdon KL, Blum J, Lento WE, Zhao C, Lagoo A, Gerrard G, Foroni L et al..  2010.  Regulation of myeloid leukaemia by the cell-fate determinant Musashi.. Nature. 466(7307):765-8. Abstract
Cortes JE, Kantarjian HM, Goldberg SL, Powell BL, Giles FJ, Wetzler M, Akard L, Burke JM, Kerr R, Saleh M et al..  2009.  High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(28):4754-9. Abstract
le Coutre P, Ottmann OG, Giles F, Kim D-W, Cortes J, Gattermann N, Apperley JF, Larson RA, Abruzzese E, O'Brien SG et al..  2008.  Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.. Blood. 111(4):1834-9. Abstract
Fungi
Khot PD, Ko DL, Fredricks DN.  2009.  Sequencing and analysis of fungal rRNA operons for development of broad-range fungal PCR assays.. Applied and environmental microbiology. 75(6):1559-65. Abstract
Fungemia
Gardner A, Mattiuzzi G, Faderl S, Borthakur G, Garcia-Manero G, Pierce S, Brandt M, Estey E.  2008.  Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(35):5684-8. Abstract
Fungal Proteins
Meeks-Wagner D, Hartwell LH.  1986.  Normal stoichiometry of histone dimer sets is necessary for high fidelity of mitotic chromosome transmission.. Cell. 44(1):43-52. Abstract
Akiyoshi B, Sarangapani KK, Powers AF, Nelson CR, Reichow SL, Arellano-Santoyo H, Gonen T, Ranish JA, Asbury CL, Biggins S.  2010.  Tension directly stabilizes reconstituted kinetochore-microtubule attachments.. Nature. 468(7323):576-9. Abstract
Dorer R, Pryciak PM, Hartwell LH.  1995.  Saccharomyces cerevisiae cells execute a default pathway to select a mate in the absence of pheromone gradients.. The Journal of cell biology. 131(4):845-61. Abstract
Hartwell LH.  1973.  Three additional genes required for deoxyribonucleic acid synthesis in Saccharomyces cerevisiae.. Journal of bacteriology. 115(3):966-74. Abstract
Toczyski DP, Galgoczy DJ, Hartwell LH.  1997.  CDC5 and CKII control adaptation to the yeast DNA damage checkpoint.. Cell. 90(6):1097-106. Abstract
Brown MT, Goetsch L, Hartwell LH.  1993.  MIF2 is required for mitotic spindle integrity during anaphase spindle elongation in Saccharomyces cerevisiae.. The Journal of cell biology. 123(2):387-403. Abstract
Stolworthy TS, Korkegian AM, Willmon CL, Ardiani A, Cundiff J, Stoddard BL, Black ME.  2008.  Yeast cytosine deaminase mutants with increased thermostability impart sensitivity to 5-fluorocytosine.. Journal of molecular biology. 377(3):854-69. Abstract
Garvik B, Carson M, Hartwell L.  1995.  Single-stranded DNA arising at telomeres in cdc13 mutants may constitute a specific signal for the RAD9 checkpoint.. Molecular and cellular biology. 15(11):6128-38. Abstract
Hartwell LH.  1974.  Saccharomyces cerevisiae cell cycle.. Bacteriological reviews. 38(2):164-98.
Battini JL, Rasko JE, Miller AD.  1999.  A human cell-surface receptor for xenotropic and polytropic murine leukemia viruses: possible role in G protein-coupled signal transduction.. Proceedings of the National Academy of Sciences of the United States of America. 96(4):1385-90. Abstract
Pryciak PM, Hartwell LH.  1996.  AKR1 encodes a candidate effector of the G beta gamma complex in the Saccharomyces cerevisiae pheromone response pathway and contributes to control of both cell shape and signal transduction.. Molecular and cellular biology. 16(6):2614-26. Abstract